Q3 EPS Estimates for Bausch Health Cos Cut by Zacks Research

Bausch Health Cos Inc. (NYSE:BHC) – Investment analysts at Zacks Research cut their Q3 2027 earnings estimates for shares of Bausch Health Cos in a research report issued on Tuesday, May 19th. Zacks Research analyst Team now forecasts that the company will post earnings per share of $1.05 for the quarter, down from their previous forecast of $1.12. The consensus estimate for Bausch Health Cos’ current full-year earnings is $4.08 per share.

Bausch Health Cos (NYSE:BHC) last announced its earnings results on Wednesday, April 29th. The company reported $0.78 EPS for the quarter, missing the consensus estimate of $0.81 by ($0.03). The firm had revenue of $2.46 billion during the quarter, compared to the consensus estimate of $2.37 billion. Bausch Health Cos had a negative return on equity of 2,922.77% and a negative net margin of 11.47%.

BHC has been the topic of several other reports. Raymond James Financial restated a “market perform” rating on shares of Bausch Health Cos in a research report on Monday, January 26th. Barclays decreased their target price on shares of Bausch Health Cos from $8.00 to $7.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 25th. Royal Bank Of Canada decreased their target price on shares of Bausch Health Cos from $10.00 to $9.00 and set a “sector perform” rating on the stock in a research report on Monday, April 27th. Wall Street Zen lowered shares of Bausch Health Cos from a “strong-buy” rating to a “buy” rating in a research report on Sunday, February 15th. Finally, Weiss Ratings downgraded shares of Bausch Health Cos from a “sell (d)” rating to a “sell (d-)” rating in a research note on Monday, May 4th. Four equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Bausch Health Cos has a consensus rating of “Reduce” and an average price target of $8.00.

Bausch Health Cos Stock Performance

Shares of BHC opened at $5.51 on Thursday. The company has a market capitalization of $2.06 billion, a PE ratio of -1.70 and a beta of 0.42. Bausch Health Cos has a one year low of $4.41 and a one year high of $8.69. The company has a debt-to-equity ratio of 54.68, a current ratio of 1.32 and a quick ratio of 0.97. The company’s fifty day moving average price is $5.42 and its 200 day moving average price is $6.13.

Institutional Investors Weigh In On Bausch Health Cos

Large investors have recently made changes to their positions in the stock. Caption Management LLC increased its position in shares of Bausch Health Cos by 101.1% during the fourth quarter. Caption Management LLC now owns 4,464 shares of the company’s stock worth $31,000 after acquiring an additional 405,789 shares in the last quarter. Caitong International Asset Management Co. Ltd increased its position in shares of Bausch Health Cos by 12,589.7% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 4,949 shares of the company’s stock worth $34,000 after acquiring an additional 4,910 shares in the last quarter. Northwestern Mutual Wealth Management Co. increased its position in shares of Bausch Health Cos by 6,661.3% during the third quarter. Northwestern Mutual Wealth Management Co. now owns 5,409 shares of the company’s stock worth $35,000 after acquiring an additional 5,329 shares in the last quarter. Russell Investments Group Ltd. increased its position in shares of Bausch Health Cos by 65.9% during the second quarter. Russell Investments Group Ltd. now owns 7,819 shares of the company’s stock worth $51,000 after acquiring an additional 3,106 shares in the last quarter. Finally, Camelot Portfolios LLC bought a new stake in shares of Bausch Health Cos during the fourth quarter worth $59,000. Institutional investors own 78.65% of the company’s stock.

Insider Buying and Selling

In other Bausch Health Cos news, Director Frank D. Lee sold 24,456 shares of the company’s stock in a transaction that occurred on Tuesday, May 19th. The shares were sold at an average price of $5.43, for a total value of $132,796.08. Following the completion of the sale, the director owned 49,339 shares of the company’s stock, valued at approximately $267,910.77. This represents a 33.14% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 20.67% of the company’s stock.

Trending Headlines about Bausch Health Cos

Here are the key news stories impacting Bausch Health Cos this week:

• Positive Sentiment: Bausch Health announced results from its 2026 Annual Meeting of Shareholders, saying all 10 director nominees were elected, including new director Eiry W. Roberts, M.D. The vote suggests continued shareholder support and adds a board member with pharmaceutical leadership experience. Bausch Health Announces 2026 Annual Meeting of Shareholder Results
• Positive Sentiment: Zacks Research nudged up its FY2026 EPS estimate for Bausch Health to $3.93 from $3.92, which is a small sign of improving near-term earnings expectations. Zacks Research FY2026 estimate update
• Neutral Sentiment: The company presented at the RBC Capital Markets Global Healthcare Conference and the Barclays Leveraged Finance Conference. These events can help investor visibility, but no major new operating update was provided in the available transcript headlines. RBC Capital Markets Global Healthcare Conference Transcript Barclays Leveraged Finance Conference Transcript
• Neutral Sentiment: Brokerage commentary reported a $8.00 price target, which is supportive but not a direct catalyst on its own. Brokerages Set Bausch Health Cos Inc. Target Price at $8.00
• Negative Sentiment: Zacks Research trimmed several longer-term earnings forecasts for Bausch Health, including FY2027, FY2028, Q2 2027, Q3 2026, and Q1 2028, signaling softer growth expectations farther out. Zacks Research earnings estimate changes
• Negative Sentiment: Director Frank D. Lee sold 24,456 shares in a pre-arranged Rule 10b5-1 transaction. While routine, insider selling can still weigh on sentiment for BHC. SEC Form 4 insider sale filing

Bausch Health Cos Company Profile

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.